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ABSTRACT
Background: Genetic variations across the SARS-CoV-2 genome may influence transmissibility 
of the virus and the host’s anti-viral immune response, in turn affecting the frequency of variants 
over time. In this study, we examined the adjacent amino acid polymorphisms in the nucleocap-
sid (R203K/G204R) of SARS-CoV-2 that arose on the background of the spike D614G change 
and describe how strains harboring these changes became dominant circulating strains globally. 
Methods: Deep-sequencing data of SARS-CoV-2 from public databases and from clinical samples 
were analyzed to identify and map genetic variants and sub-genomic RNA transcripts across the 
genome. Results: Sequence analysis suggests that the 3 adjacent nucleotide changes that result in 
the K203/R204 variant have arisen by homologous recombination from the core sequence of the 
leader transcription-regulating sequence (TRS) rather than by stepwise mutation. The resulting 
sequence changes generate a novel sub-genomic RNA transcript for the C-terminal dimerization 
domain of nucleocapsid. Deep-sequencing data from 981 clinical samples confirmed the pres-
ence of the novel TRS-CS-dimerization domain RNA in individuals with the K203/R204 variant. 
Quantification of sub-genomic RNA indicates that viruses with the K203/R204 variant may also 
have increased expression of sub-genomic RNA from other open reading frames. 
Conclusions: The finding that homologous recombination from the TRS may have occurred 
since the introduction of SARS-CoV-2 in humans, resulting in both coding changes and novel 
sub-genomic RNA transcripts, suggests this as a mechanism for diversification and adaptation 
within its new host.
Keywords: COVID-19; SARS-CoV-2; homologous recombination; sub-genomic RNA transcript; 
transcription-regulating sequence; viral polymorphism
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INTRODUCTION
It is thought that SARS-CoV-2 originated from a bat coronavirus transmitted to humans, like-
ly via an intermediate host such as a pangolin, acquiring a furin-cleavage site in the process. 
This new motif allows cleavage at the boundary of the S1 and S2 domains of the spike protein 
in virus-producing cells [1]. A SARS-CoV-2 variant in the spike protein, D614G (B.1 lineage), 
emerged early in the epidemic and has rapidly became dominant in virtually all areas of the world 
where it has circulated [2]. Several studies have shown this variant to be associated with high-
er viral RNA levels in the upper respiratory tract, higher titers in pseudoviruses in vitro [2, 3], 
and increased infectivity [4, 5]. More recently, emerging lineages from this genetic background 
(B.1.1.7 – ‘Alpha or UK variant’, B.1.351 – ‘Beta or South African variant’, or B.1.617.2 - ‘Delta 
variant’) have been identified with reported rapid local expansions of these viruses. 
The diversification of coronaviruses can occur via point mutations and recombination events [6, 
7] that can result in increased prevalence due to selective advantage related to increased infec-
tiousness and transmission of the virus or by chance. Evidence of viral adaptation to selective 
pressures as a virus spreads among diverse human populations has important implications for the 
ongoing potential for changes in viral fitness over time, which in turn may impact transmissibili-
ty, disease pathogenesis, and immunogenicity. Furthermore, the functional impact of new genetic 
changes needs to be considered in the performance of diagnostic tests, ongoing public health 
measures to contain infection around the world, and the development of universal vaccines and 
antiviral therapies including monoclonal antibodies. 
Here we examined a variant of SARS-CoV-2 that emerged within the subset of sequences har-
boring the D614G variant and contains 3 adjacent nucleotide changes spanning 2 residues of the 
nucleocapsid protein (R203K/G204R; B.1.1 lineage), which has resulted in a novel sub-genomic 
RNA transcript. Sequence analysis suggests these changes are the result of homologous recombi-
nation from the core sequence of the leader transcription-regulating sequence (TRS). This event 
introduced a new TRS between the RNA binding and dimerization domains of nucleocapsid 
providing the template for the generation of a novel sub-genomic RNA transcript. Further novel 
sub-genomic RNA transcripts arising in association with incorporation of leader sequence and 
TRS were also observed, suggesting homologous recombination from this region as a potential 
mechanism for SARS-CoV-2 diversification and adaptation within its new host.
METHODS
Study Design 
This study utilized deposited SARS-CoV-2 genomic sequences in public databases, with a further 
981 Oxford Nanopore Technology genomes and clinical metadata from Sheffield, United King-
dom, as a validation set, to identify and map genetic variants and sub-genomic RNA transcripts 
across the genome. Accession numbers and links to datasets are in Supplementary Material. 
SARS-CoV-2 sequence generation from patients with COVID-19
SARS-CoV-2 sequences, with matched clinical metadata, were generated using samples taken for 
routine clinical diagnostic use from 981 individuals presenting with COVID-19 disease to Shef-
field Teaching Hospitals NHS Foundation Trust, Sheffield. This work was performed under ap-
proval by the Public Health England Research Ethics and Governance Group for the COVID-19 
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Genomics UK consortium (R&D NR0195). Following extraction, samples were processed using 
the ARTIC Network SARS-CoV-2 protocol. After RT-PCR, SARS-CoV-2 specific PCR and library 
preparation with Oxford Nanopore LSK-109 and barcoding expansion packs NBD-104 and NBD-
114 samples were sequenced on an Oxford Nanopore GridION X5 using R9.4.1D flow cells. Bases 
were called with either the fast or high accuracy basecaller, Guppy (Oxford Nanopore Technol-
ogies), with demultiplexing enabled and set to --require-both-ends. Samples were then analyzed 
using ARTIC Network pipeline v1.1.0rc1. 
SARS-CoV-2 sequence acquisition from public repositories 
Complete SARS-CoV-2 genome sequences were downloaded from the GISAID EpiCoV reposi-
tory on 24th January, 2021 (https://www.gisaid.org/). The complete dataset of 455,774 sequences 
with coverage across the genome were aligned in CLCbio Genomics Workbench 12 (QIAGEN 
Bioinformatics) to the GenBank reference sequence NC_045512.2. Aligned sequences were 
exported in FASTA format and imported into Visual Genomics Analysis Studio (VGAS), an 
in-house program for visualizing and analyzing sequencing data (https://www.iiid.com.au/soft-
ware/vgas) [8].The chronological appearance of the sequences was generated using the collection 
dates for each of the sequences. Of note, our current knowledge of the global circulating variants 
is dependent on the ability of laboratories in different countries to deposit full genome length 
SARS-CoV-2 sequences and may be subject to ascertainment bias. As such, the frequencies of 
specific variants shown may not reflect the size of the outbreak. However, the data does provide 
the opportunity to predict the presence of specific variants in areas given the known epidemiolo-
gy within different countries and regions. A subset of subjects also had individual deep sequence 
reads deposited in the Sequence Read Archive (SRA) at www.ncbi.nlm.nih.gov/sra. These se-
quence reads were downloaded and aligned as indicated above. 
Identification of amino acid substitutions 
Codon usage output allowed for identification of amino acid substitutions across the SARS-Cov-2 
genome. A cut-off of 5% frequency within the consensus SARS-CoV-2 protein sequences was set 
to obtain the codon usage across all sequences and is shown in Supplemental Table 1. The viral 
polymorphisms detected are present in viral variants sequenced using different NGS platforms 
(eg, nanopore, Illumina) and the Sanger-based sequencing method making it unlikely that the 
new changes are sequence or alignment errors. In addition, different laboratories around the 
world have deposited sequences with these polymorphisms in the database and examination of 
individual sequences in the region failed to uncover obvious insertions/deletions likely represent-
ing alignment issues or homopolymer slippage. 
HLA peptide binding prediction 
The region containing the adjacent amino acid polymorphisms in the nucleocapsid was divided 
into sliding windows of 8-14 amino acids. NetMHC 4.0 (s) and NetMHCpan 4.0 (http://www.cbs.
dtu.dk/services/NetMHCpan/) with default settings were utilized to predict HLA-class I bind-
ing scores and binding differences across all HLA class-I alleles for the original 2003 SARS and 
current SARS-CoV-2 sequences harboring the R203/G204 and K203/R204 polymorphisms in the 
nucleocapsid (output listed in Supplemental Table 2). 
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HLA peptide binding assays 
MHC was purified from the Steinlin EBV transformed homozygous cell line (IHWG ID: 9087; 
A*01:01, B*08:01 and C*07:01) using the B123.2 (anti-HLA-B, C) and W6/32 (anti-MHC class 
I) monoclonal antibodies, and classical MHC-peptide inhibition of binding assays performed, 
as previously described [9]. To develop an HLA C*07:01-specific binding assay, the IEDB was 
utilized to identify candidate peptides reported as HLA-C*07:01 epitopes or eluted ligands. One 
peptide (3424.0028; sequence IRSSYIRVL, Macaca mulatta and Homo sapiens DNA replication 
licensing factor MCM5 289-297) was radiolabeled and found in direct binding assays to yield a 
strong signal with as little as 0.5nM MHC. Subsequent inhibition of binding assays established 
that 3424.0028 bound with an affinity of 0.21nM. To establish that the putative assay was spe-
cific for C*07:01, and not co-purified B*08:01, an additional 2 peptides previously reported as 
HLA-C*07:01 ligands were also tested, with one found to bind with high affinity (IC50 67nM) 
and the other with intermediate (IC50 1600nM). At the same time, a panel of known B*08:01 
ligands was not found to have the capacity to inhibit binding of radiolabeled 3424.0028 (Sup-
plemental Table 3). By contrast, when the same panel of peptides was tested in the previously 
validated B*08:01 assay [10], 3424.0028 was found to bind with about 1500-fold lower affinity, all 
of the known B*08:01 ligands bound with IC50s <10nM, and the C*07:01 ligands with affinities 
>1000nM. 
Sub-genomic RNA classification and quantification in the Validation Dataset 
We developed a tool, “periscope” (v0.0.0), to classify and quantify sub-genomic RNA in the 
Sheffield ARTIC network Nanopore dataset [11]. The tool can be downloaded from git-hub at 
https://github.com/sheffield-bioinformatics-core/periscope. Briefly, this tool uses local alignment 
to identify putative sub-genomic RNA supporting reads and uses genomic reads from the same 
amplicon to normalize. 
RNA structure modeling 
The RNAfold program from the ViennaRNA Web Server (http://rna.tbi.univie.ac.at/) was used 
for structural predictions using the default settings, and the minimum free energy structures were 
acquired using the base-pairing probability color scheme. The Dot-bracket folding notations were 
obtained for each of the R203K/G204R sequences and used for Junction Explorer (nature.njit.
edu/biosoft/Junction-Explorer/) and CHS-align (nature.njit.edu/biosoft/CHSalign/). 
Statistical Analysis 
Fisher exact test was used to compare the proportion of individuals with specific sub-genom-
ic RNA transcripts. P values less than 0.05 were used as the statistical threshold. Comparisons 
between sub-genomic and genomic RNA expression in R203/G204 compared to K203/R204 
containing sequences were made using the Mann-Whitney U test, corrected for multiple compar-
isons using the Holm method. Logistic and linear regression modeling was used to explore the 
impact of K203/R204 and other co-variates on hospitalization, CT values, and sub-genomic RNA 
expression. 
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RESULTS AND DISCUSSION 
Adjacent nucleocapsid polymorphisms emerged from the existing spike protein D614G variant 
We utilized publicly available SARS-CoV-2 sequences from the GISAID database (available on 
the 24th January, 2021; www.gisaid.org) to identify amino acid polymorphisms arising in global 
circulating forms of the virus in relation to region and time of collection. Of the 455,774 circulat-
ing variants there were 29 amino acid polymorphisms present in >5% of the deposited sequences 
(of a total of 9413 sites; Supplemental Table 1) including the spike D614G variant (B.1 lineage) 
that emerged early in the pandemic and the adjacent R203K/G204R variants (B.1.1 lineage) in the 
nucleocapsid protein [12] that formed one of the main variants emerging from Europe in early 
2020. As of the end of January 2021, the K203/R204 variant comprises 37.4% of globally reported 
SARS-CoV-2 sequences (Figure 1) and almost exclusively occurs on the D614G genetic back-
ground (Supplemental Table 4). 
Figure 1. Proportion of weekly deposited SARS-CoV-2 sequences globally (n=455774). The D614G 
(B.1) variant has become one of the dominant forms globally between January 2020 and January 2021. 
Note a small proportion of deposited sequences did not include information regarding specific collection 
date and as such were excluded.
Although the D614G change rapidly increased in prevalence in almost all regions, the prevalence 
rates of the K203/R204 subset of the D614G variant are variable in different geographic areas and 
over time (Figure 2). For example, an almost complete replacement of D614 by G614 was noted in 
South America between March and April 2020, and a similar replacement pattern was seen with 
the K203/R204 variant, most marked in Chile, Argentina, and Brazil [13]. A closer examination 
of the deposited sequences in the United Kingdom shows the K203/R204 variant increasing in 
prevalence early in 2020, but the second wave later in the year shows a shift in the proportion of 
deposited sequences with the R203/G204 subset of the D614G variant (B.1.177 lineage) until the 
more recent appearance of the B.1.1.7 ‘Alpha or UK variant’ that harbors the K203/R204 polymor-
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phisms (Supplemental Figure 1 and Supplemental Table 4); supporting a likely increased infectiv-
ity of this variant. 
Figure 2. Proportion of weekly deposited SARS-CoV-2 sequences by region. The proportion of R203/
G204 to K203/R204 sub-variants of the D614G variant differs in different regions between January 2020 
and January 2021 with recent increases in the frequency of new variants.
Amino acid polymorphisms due to 3 adjacent nucleotide changes in the nucleocapsid likely due to 
homologous recombination 
Of the publicly available sequences examined with the 2 amino acid polymorphisms K203/R204, 
all showed the 3 adjacent nucleotide changes from AGG GGA to AAA CGA. There was no differ-
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ential codon usage for the K203/R204 variant in the database. However, there was evidence of low 
frequency alternative codon usage for arginine at 203 (AGA) for the R203/G204 variant and for 
lysine (AAG) at 203 for the K203/G204 variant (Supplemental Table 3). Overall, circulating vari-
ants that contain the intermediate codon as the consensus that could facilitate a single step from 
the AGG arginine codon to the AAA lysine codon at position 203 appear rare among captured 
variants to date (Supplemental Table 5). Furthermore, a K203 polymorphism alone was seen in 
0.3% and an R204 polymorphism alone seen in only 0.02% of sequences (Supplemental Table 
5). The low frequency K203/L204 and K203/P204 variants are both one nucleotide step from the 
K203/R204 variant, have been deposited into the public databases (November 2020) well after 
the emergence of the K203/R204 variant (February 2020), and accordingly likely arose from this 
genetic background.
The rapid emergence of closely linked polymorphisms in viruses can also reflect strong selec-
tion pressure on this region of the genome, in which the original mutation incurred a replica-
tive capacity, or other fitness cost, which could be restored by a linked compensatory mutation. 
Evidence for such adaptations with closely linked compensatory mutations are known to occur 
under host immune pressure as is well established for other RNA viruses such as HIV [14–16] 
and Hepatitis C virus [17]. In the absence of anti-viral treatment, these viruses have such a high 
rate of viral replication, error-prone polymerases, and lack of associated proofreading, mismatch 
repair, and other nucleic acid repair pathways that they generate a swarm of viral variants with 
ongoing recombination between variants (in the case of HIV) being generated continuously. As 
a result, selection pressure exerted by immune responses or other selective pressures effectively 
operate on each separate residue independently [16]. In contrast, coronaviruses encode proof-
reading machinery and have a propensity to adapt by homologous recombination between virus-
es [6] rather than by classic stepwise individual mutations driven by selective pressures effectively 
operating on individual viral residues. Furthermore, a simulation based on the nucleocapsid 
genomic region and allowing up to 10 random mutations indicates the likelihood of observing 3 
consecutive nucleotide changes is less than 0.0005. These findings argue against stepwise change 
of the nucleotides for the R203K/G204R variant. 
The introduction of the AAACGA motif by homologous or heterologous recombination is a more 
parsimonious mechanistic explanation and would have immediately resulted in both an R to K 
change and adjacent G to R amino acid change at the positions 203 and 204, respectively. It is crit-
ical to determine if the introduction of the AAACGA motif has induced any replicative or other 
fitness change for the virus, as a result of either structural or functional changes in the RNA or the 
concomitant change of amino acids from R203/G204 to K203/R204 and any related structural or 
functional impact on the nucleocapsid protein.
SARS-CoV-2 itself as likely source for homologous recombination 
To identify possible viral sources for homologous recombination with SARS-CoV-2, we initially 
performed a search of the motif in the nucleocapsid in related beta coronaviruses from human 
and other species in the public databases and only found the presence of the R203/G204 combi-
nation. We performed a similar search in our metatranscriptome data generated from a cohort 
study consisting of 65 patients of whom 43 had acute respiratory infections and 22 were asymp-
tomatic. From the data, we assembled nearly complete and coding complete viral genomes of the 
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Coronavirus (NL63 - alpha, OC43 - beta, 229E - alpha), RSV (A, B), Rhinovirus (A, B, C), Influ-
enza (A - H3N2), and Bocavirus family. None of the alpha coronaviruses had the R203/G204 or 
K203/R204 combination or indeed any variation at these sites (n=14; sequence depth >3000). We 
then performed a search for stretches of similarity using varying window sizes (>14 base pair (bp) 
including the motif) in all sequences. A 14bp window was selected as 14bp has been shown to be 
the minimum amount of homology required for homologous recombination in mammalian cells 
[18] No significant hits were identified. However, the AAACGA sequence encoding the K203/
R204 amino acids overlaps with the CTAAACGAAC motif of the leader transcription-regulat-
ing sequences (TRS; core underlined) [19] of SARS-CoV-2 itself and this core sequence motif is 
also found near the start codon of the protein for surface glycoprotein (S), ORF3a, E, M, ORF6, 
ORF7a, ORF8, ORF10, and nucleocapsid, in keeping with its known roles in mediating template 
switching and discontinuous transcription [19].
Deep sequencing confirms quasi-species with the leader sequence linked to known or introduced  
TRS region
Discontinuous transcription of SARS-CoV-2 results in sub-genomic RNA (sgRNA) transcripts 
containing 5'-leader sequence-TRS-start codon-ORF-3'. These RNA transcripts should also be 
captured from reads generated from NGS platforms. We therefore reasoned we should be able 
to find such sequences within deep-sequencing reads at the sites of known sub-genomic regions 
(corresponding to the ORFs) and adjacent to position 203/204 of the nucleocapsid in patients 
infected with the K203/R204 variant but not in those with the R203/G204 variant (Figure 3). 
We searched for sgRNAs in sequence data generated from 981 patients with COVID-19 based 
on the ARTIC network protocol (https://artic.network/ncov-2019; Figure 3) and subsequent 
Nanopore sequencing in Sheffield. As expected, the most frequent sgRNA transcripts in each 
patient, irrespective of variant, corresponded to the known regions containing the start codon of 
the SARS-CoV-2 proteins (Figure 4A). However, out of a total of 550 K203/R204 sequences, 231 
had evidence (>=1 read containing leader sequence at the novel TRS site) of the non-canonical 
nucleocapsid sgRNA (42%), but only 1 out of a total of 431 R203/G204 patients had evidence of 
the novel sgRNA (this is likely a false positive as described in Supplemental Figure 2). 
We confirmed the presence of the novel non-canonical nucleocapsid sgRNA in 27/45 individuals 
with the K203/R204 variant but in none of 45 individuals with the R203/G204 variant (Fisher 
test, P=5.0e-11; Supplemental Table 6) from the sequence read archive (SRA) database (www.
ncbi.nlm.nih.gov/sra). Interestingly, we also found the presence of 23 other non-canonical sgRNA 
transcripts with the 5’-leader-TRS-start codon-3’ at low frequency in these 90 patients (irrespec-
tive of variant), due to multiple adjacent changes to the consensus sequence across the genome 
generating new core TRS motifs (including with minor mismatches) (Supplemental Table 6). It 
should be noted that none of these changes are present in the consensus sequence of the SARS-
CoV-2 genomes downloaded and represent low frequency quasispecies within individuals. It 
does, however, suggest other instances of the introduction of the core sequences from the leader 
TRS elsewhere in the SARS-CoV-2 genome. 
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Figure 3. The configuration of canonical sgRNAs and the novel non-canonical nucleocapsid sgRNA 
(N*) in SARS-CoV-2. The bottom bar illustrates the presence of the leader sequence (blue text) followed 
by the transcription-regulating sequence (TRS; red text) within the genomic sequence that continues into 
the first ORF 1a. The presence of other canonical sgRNA transcripts in which the leader sequence and 
TRS precede the start codon (methionine; pink) of the other proteins are shown. The presence of the novel 
non-canonical sgRNA transcript containing the K203/R204 polymorphisms (N*) is shown. The ARTIC 
primer locations and resultant amplicons are shown.
SARS-CoV-2 viruses with K203/R204 are not associated with increased hospitalization with COVID-19 
or higher virus levels in the upper respiratory tract
The same dataset from COVID-19 patients in Sheffield was used to explore whether the K203/R204 
variant had any association with clinical outcome. The median age of this cohort was 54 years (IQR 
38 to 74) and 59.8% were female. Of these, 440 (44.9%) were hospitalized COVID-19 patients and 
42 (4.3%) subsequently required critical care support. A multivariable logistic regression model in-
cluding 203/204 status, age, and sex showed no association of K203/R204 with hospitalization (OR 
0.82, 95% confidence intervals (CI 0.58 – 1.16), P=0.259). As expected, higher age and male sex 
were significantly association with hospitalization with COVID-19 (OR 1.09, 95% CI 1.08 – 1.11, P 
<2e-16 for age and OR 4.47, 95% CI 3.13 – 6.43, P=2.91e-16 for male sex). Male sex, but not age or 
203/204 status, was associated with risk of critical care admission (Supplemental Table 7). 
We explored whether K203/R204 was associated with greater virus levels in the upper respiratory 
tract as estimated by cycle threshold (CT) values from the diagnostic RT-PCR. As day of illness will 
impact CT value, we focused on a subset of the cohort (n=478) where this information was available 
(all non-hospitalized patients, median symptom day 3, range 1–13 days). Data were analyzed with 
sequences stratified by spike 614 and nucleocapsid 203/204 status (D614/R203/G204, G614/R203/
G204, and G614/K203/R204). Multivariable linear regression models showed no impact of G614/
K203/R204 compared to G614/R203/G204 status on CT values (P= 0.83, Supplemental Table 6B), 
but as expected, later day of symptom onset was significantly associated with higher CT values, 
therefore lower viral load (Supplemental Table 8, P=2.05E-05). Consistent with recent findings [2], 
presence of a spike D614G variant was significantly associated with lower CT values (higher viral 
loads) in the same subset of individuals, even when day of illness at sampling is included in the mod-
el (Supplemental Table 8A, D614/R203/G204 vs G614/R203/G204, P=0.00011, Figures 5A and B). 
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Figure 4. Exploration of sgRNAs in 981 samples from Sheffield, United Kingdom. A. A heatmap 
showing presence or absence of sgRNAs from different ORFs. K203/R204 (KR)-containing sequences 
have evidence of the novel truncated N ORF sgRNA (N*, red, 233/553, 42%). An ORF sgRNA was deemed 
present if we could find >=1 read in support. Heatmap is ordered by the presence or absence of the novel 
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sgRNA. There were a total of 448 R203/G204 (RG)-containing sequences and 1 had evidence of a novel 
sgRNA (likely false positive, Figure S2). B. Significantly higher (Mann-Whitney U P < 2.2e-16) total 
sgRNA in KR-containing compared to RG-containing sequences. C. Sub-genomic RNA is significantly 
increased in KR-containing compared to RG-containing sequences for a number of ORFs, most notably 
nucleocapsid (N; Mann-Whitney U P = 2.06e-37 corrected for multiple testing using the Holm method). 
Y-axis denotes square root transformed sub-genomic reads normalized to 100,000 genomic reads from 
the same ARTIC amplicon. D. There is no difference in genomic RNA levels (normalized to total mapped 
reads) between KR- and RG-containing sequences. *novel sgRNA, ORF10, and ORF1a are excluded from 
this analysis due to ORF10 not being expressed, difficulty in discriminating ORF1a sgRNA from genomic 
RNA, and the novel truncated N sgRNA only being present in KR-containing sequences. *** < 0.001, ** < 
0.01, * < 0.05. All P values shown are following correction for multiple testing with the Holm method.
SARS-CoV-2 viruses with K203/R204 have evidence of higher sub-genomic RNA expression 
We hypothesized that the amount of sgRNA at each of the ORF TRS positions in the SARS-
CoV-2 genome in ARTIC nanopore sequencing data could serve as a proxy for expression levels 
of each of the ORFs due to their positions in the amplicons (Figure 3). To test this hypothesis we 
developed a tool, periscope [11], which quantifies the number of sgRNA and genomic RNA reads 
at each ORF TRS position in ARTIC network nanopore sequencing data. We applied periscope to 
the 981 sequences in the Sheffield validation dataset. To control for the sequencing depth differ-
ences evident between amplicons, we determined the amplicon that shares the 3' primer with the 
sgRNA reads and used the total count of genomic RNA at this amplicon to calculate the propor-
tion of sgRNA for each ORF. The N ORF sgRNA is expressed at high levels in all samples. ORF10 
sgRNA was absent as others have shown [20]. A significant increase in sgRNA levels for several 
ORFs in samples with K203/R204 compared to R203/G204 samples is apparent (Figure 4B). N is 
the most striking example (Figure 4C, Mann-Whitney U test p value, adjusted for multiple testing 
P = 2.06e-37), but sgRNA from ORFs E, M, and ORF6 are also significantly increased. There is 
no significant difference in genomic RNA levels (Figure 4D, normalized to total mapped reads) 
between these 2 groups. 
As discussed above, the K203/R204 variants appear to have emerged within the subset of SARS-
CoV-2 sequences with a D614G variant in the spike protein, which has been associated with in-
fections with a higher viral load in the upper respiratory tract. To explore whether the differences 
between K203/R204 and R203/G204 sequences in sgRNA quantities were due to D614 compared 
to G614 variant differences, we repeated the comparisons following further stratification of 
sequences. Interestingly, G614/R203/G204 variants showed lower total sgRNA expression than 
D614/R203/G204 samples (Supplemental Figure 3). Of note, sgRNA for spike (S), membrane (M) 
and envelope (E) ORFs were significantly higher in samples with D614/R203/G204 compared to 
those with G614/R203/G204 (adjusted P values 1.02e-4 for S, 0.0495 for M and 0.00696 for E). 
Total sgRNA in G614/K203/R204-containing samples was still significantly higher than in G614/
R203/G204 samples (Supplemental Figure 3A, Mann-Whitney U test P value, adjusted for mul-
tiple testing P = 3.5e-6). Similar increases in some individual ORF sgRNA quantities in G614/
K203/R204 compared to G614/R203/G204 sequences were also seen, most notably for nucleocap-
sid (Supplemental Figure 3B, adjusted P value 1.34e-12). 
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To ensure that the increase in sgRNA in K203/R204-containing sequences was not due to con-
founding by differences in sampling date compared to date of symptom onset, we evaluated the 
impact of K203/R204 and day of illness on sgRNA expression in a multivariable linear regression 
model using the subset of 478 sequences described above (stratified by D614/R203/G204, G614/
R203/G204 and G614/K203/R204 status). Higher sgRNA levels were significantly associated with 
later day from symptom onset (Supplemental Table 9, P=9.9E-08). G614/R203/G204 compared to 
D614/R203/G204 was again associated with a reduction in sgRNA levels (P=0.011, Supplemental 
Table 9A), whereas a K203/R204 change on the background of spike G614-containing sequences 
was associated with a significant increase in sub-genomic RNA (P=4.51E-05, Supplemental Table 
9B). Spike canonical sub-genomic RNA was higher in D614/R203/G204 samples, whereas nucle-
ocapsid canonical sub-genomic RNA was higher in G614/K203/R204 samples (Figure 5C and D, 
Supplemental Figure 3).
Figure 5. Spike 614 and Nucleocapsid 203/204 Status, Diagnostic Metrics, and level of sub-genomic 
and genomic RNA. A. E gene cycle threshold (CT) normalized to RNase P CT stratified by variant status 
in N = 478 individuals from Sheffield dataset with day of symptom onset data available. This normalization 
was done to combine and display E gene CT data from 2 different extraction protocols. Y-axis reversed to 
aid interpretation, as lower normalized CT values equal higher virus levels. B. Normalized E gene CT vs 
the day of sampling from day of symptom onset. P values provided are from a generalized multivariable 
linear regression model (GLM) for the difference in normalized E gene CT value between samples 
containing each variant, with extraction method and day of illness included in the model (Table S6). 
C. Normalized (per 1000 genomic reads) sgRNA levels for ORFs S and N. D. Normalized (per 100,000 
mapped reads) genomic RNA levels for ORFs S and N.
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RT-PCR assays have been developed to directly assess sub-genomic mRNA (sgRNA) as a measure 
of replicative intermediates of SARS-CoV-2 representing putative replication in cells rather than 
RNA packaged in virions or residual viral RNA [21, 22]. A decline in sgRNA in sputum typically 
occurs from day 10 to 11 after onset of symptoms [22]. Our findings that a variant can emerge 
that is associated with a novel sub-genomic RNA or may differentially impact the level of differ-
ent sgRNAs suggest that the viral sequences should be analyzed to ensure the primers or probes 
used are appropriate and analysis of short-read deep sequences with the periscope tool should be 
considered to help interpret results obtained from different variants. 
Potential impact of introduced TRS sequences on RNA structure 
Modeling of the region around the mRNA encoding position 203 and 204 of the nucleocapsid us-
ing RNAfold [23] predicts the presence of a 3-way junction in the RNA (Supplemental Figure 4), 
which was also predicted using Junction-Explorer [24]. The 3-way junction motifs are common 
throughout biology and are found both in pure RNAs, such as riboswitches or ribozymes, and in 
RNA-protein complexes, including the ribosome [25]. RNA 3-way junctions are often stabilized 
via terminal loop interactions with distant tertiary contacts while the junctions act like flexible 
hinges. These attributes allow these structures to sample unusual conformational spaces and they 
often form platforms for interactions with other molecules such as proteins, RNAs, or small mole-
cule ligands [25], and these folds often have an essential role in either the function or assembly of 
the molecules in which they are contained. 
RNAfold predicts the mutation from AGGGGA to AAACGA strongly disrupts this structure 
as the lengths of the predicted helices and each of the junctions are altered and the stability of 
Helix 2 is undermined (Supplemental Figure 4). A comparison of the 2-modeled sequences using 
CHSalign [26] also indicates that none of the junctions are maintained. Given these widespread 
alterations, this modeling predicts that the AGGGGA to AAACGA mutation would have a strong 
impact on the local RNA structure of this region, and likely impacts the normal function of this 
3-way junction motif. Interestingly, the RNA modeling shown in Supplemental Figure 4 also 
suggests that pairing of specific nucleotides to maintain these RNA structures may require the 
preferential codon usage by RG (AGGGGA) and KR (AAACGA) and be a contributory factor to 
preferential codon usage in RNA viruses more generally even in protein coding regions. 
While it is not possible to determine the impact of this proposed structural alteration on SARS-
CoV-2 without a defined function for this structure, there are precedents where minor changes in 
a 3-way junction have large functional consequences for their host viruses. For example, Flavivi-
ruses such as Dengue and West Nile virus utilize the host cell machinery to degrade viral ge-
nomes until they encounter structures near the 3' end that are resistant to XRN1 5'-3' exonuclease 
[27]. The resulting small flaviviral RNAs (sfRNAs) are non-coding RNAs that induce cytopathic-
ity and pathogenicity. The resistance of sfRNA to XRN1 is dependent on the structure of a 3-way 
junction, and a single nucleotide change at the junction alters the fold sufficiently to prevent the 
accumulation of disease-related sfRNAs. Thus, small changes at the nucleotide level can have pro-
found functional consequences for viral RNA 3-way junctions.
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Lack of evidence that the RG to KR change at positions 203 and 204 of nucleocapsid was driven by 
HLA-restricted immune selective pressure 
Selection of viral adaptations to polymorphic host responses mediated by T cells, NK cells, and 
antibodies are well described for other RNA viruses such as HIV and HCV [16, 28]. HIV-1 ad-
aptations to human leucocyte antigen (HLA)-restricted T-cell responses have also been shown 
to be transmitted and accumulate over time [29, 30]. As previously shown for SARS-CoV, T-cell 
responses against SARS-CoV-2 are likely to target the nucleocapsid [31]. Notably, SARS-CoV-2 
R203K/G204R polymorphisms modify the predicted binding of putative HLA-restricted T-cell 
epitopes containing these residues (Supplemental Table 2). One of the predicted T-cell epi-
topes is restricted by the HLA-C*07 allele; and we therefore considered whether escape from 
HLA-C-restricted T-cell responses may conceivably confer a fitness advantage for SARS-CoV-2, 
particularly in European populations where HLA-C*07 is prevalent and carried by >40% of the 
population (www.allelefrequencies.net). However, using HLA-C*07:01 purified from the Steinlin 
cell line (IHWG ID: 9087; A*01:01, B*08:01, and C*07:01) and the anti-HLA Class I B123.2 mAb 
in inhibition assays we were not able to detect binding of either of the SARS-CoV-2 peptides 
SRGTSPARM or SKRTSPARM (S3 Table). We therefore have, as yet, no evidence of any impact or 
selective advantage to the virus at the protein level of a change at position 203/204 from the RG to 
KR residues. 
SARS-CoV-2 and Host Adaptation: Implications for global viral dynamics, pathogenesis and 
immunogenicity
Currently the possible functional effect(s) of the introduction of the AAACGA motif from the 
leader TRS into the RNA encoding position 203 and 204 of the nucleocapsid at the RNA and 
protein level are not known. TRS sites are usually intergenic, and it has been assumed that re-
combination events at such sites are more likely to be viable. It has also been shown recently that 
recombination breakpoint hotspots in coronaviruses are more frequently co-located with TRS-B 
sites than expected [32]. Our findings suggest that a novel TRS-B site can be introduced in a re-
combination breakpoint from the leader TRS, and that this can occur within an ORF and remain 
viable. The exact mechanism by which the AAA CGA codons could have been incorporated from 
the TRS-L into the nucleocapsid is not known but may have first required the AAACGA to be 
captured from the TRS-L and then for replication to be reinitiated at the nucleocapsid to generate 
a full-length genomic RNA. 
The nucleocapsid protein is a key structural protein critical to viral transcription and assembly 
[33], suggesting that changes in this protein could either increase or decrease replicative fitness. 
The K203/R204 polymorphism is located between the RNA binding/serine-rich domains and 
the dimerization structural domain (Supplemental Figure 5) in a part of the protein that has not 
been characterized in terms of 3-dimensional structure. The sequence of this region is not similar 
enough to solved structures to allow prediction of the influence of the K203/R204 polymorphisms 
on the structure or function of the protein. However, it is known that SARS-CoV-2 is exquisite-
ly sensitive to interferons, and that it depends on the nucleocapsid and M proteins to maintain 
interferon antagonism [34, 35]. Specifically the C terminus (aa 362 to 422) of the nucleocapsid, 
which is predicted to be expressed at higher levels in those with the KR variant and novel sgR-
NA, has been shown to interact with the SPRY domain of tripartite motif protein 25 (TRIM25) 
disturbing its interaction with caspase activation and recruitment domains (CARDs) of retinoid 
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acid-inducible gene I (RIG-I) inhibiting RIG-I ubiquitination and Type 1 interferon signaling 
[36]. Importantly the cells expressing the C-terminal nucleocapsid protein in that study produced 
lower viral titer, suggesting the incorporation of this protein into the nucleocapsid may reduce 
the formation of functional virus. This raises the possibility that any enhancement of inhibition 
of interferon signaling associated with the novel K203/R204 sgRNA may be offset by less effi-
cient replication, potentially accounting for the lack of association with higher viral load in the 
upper respiratory tract and absence of epidemiologic evidence of increased transmission. It is 
also possible that the increase in sgRNA directly inhibits RIG-I signaling and downstream Type I 
interferon responses as has been described for Dengue serotype 2 [37]. Finally, the central region 
of the coronavirus nucleocapsid (aa 117 to 268) has been shown to have RNA chaperone activity 
that enhances template switching and efficient transcription possibly accounting for the increase 
in sgRNA for the E and M proteins and ORF6 in KR-sequences compared to RG-sequences [38]. 
Note, we cannot exclude that the novel sgRNA may also use the downstream ATG in the ORF9c 
reading frame.
The adaptive potential of differential expression of sgRNAs is supported by a recent study by 
Thorne and colleagues that demonstrates that the B.1.1.7 (‘Alpha’ or UK variant) isolate con-
taining the R203K/G204R substitutions is associated with enhanced antagonism of the innate 
immune response [39]. Specifically, this study showed that in-vitro infection of human lung 
epithelial (Calu-3) cells by B.1.1.7 isolates showed diminished RNA and protein expression of 
IFNb and reduced induction of interferon sensitive genes relative to other isolates without these 
defining mutations in the nucleocapsid (normalized for intracellular viral RNA). This effect was 
independent of the reduced sensitivity to type I and III IFNs described for isolates carrying the 
D614G spike mutation [40]. Further evaluation of this system showed that infection with the 
B.1.1.7 isolate resulted in significant changes in protein expression of known innate immune 
regulators such as ORF9b [41], ORF6 [42], and nucleocapsid [36, 43]. Their study also provides 
experimental confirmation of our findings that N* sgRNA levels are high and unique to isolates 
with the R203K/G204R mutations. These increased levels of sgRNAs and protein support the 
findings in this study showing increased sgRNA levels for N, ORF6, and N* in clinical samples 
from B.1.1.7-infected patients relative to patients infected with other SARS-CoV-2 variants. Inter-
estingly, the increased levels of ORF9b may be due to the D3L mutation in the nucleocapsid that 
we have proposed to have arisen similarly to the R203G/G204R mutations and is associated with 
increased levels of B.1.1.7 sgRNA encoding ORF9b in clinical samples [44]. 
The B.1.617.2 (‘Delta’) variant appears to be more transmissible even in the context of previous 
vaccination and is now replacing other variants in 2021. This variant has acquired an R203M 
substitution as a result of a single nucleotide change while retaining glycine (G) at position 204. 
This raises the possibility that the residue 203 is critical to the interaction of nucleocapsid with 
TRIM25 decreasing the Type 1 interferon response, or increases transmissibility in some other 
way [36].
Other contemporary concerns include the fall in antibody levels following infection or vaccina-
tion, the potential limited durability of protection afforded by currently available vaccines, and 
the risk of reinfection by variants after vaccination [45, 46]. At low levels of antibodies, the lungs 
appear to remain relatively protected against severe disease presumably by some combination of 
antibodies and amnestic responses restimulated by the time the lung is involved. In contrast, the 
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early establishment of infection in the upper respiratory tract appears possible if antibody levels 
are low [47]. We therefore postulate that variants that are more effective in interfering with Type 1 
interferon or other early responses would be more transmissible, but not necessarily cause severe 
disease in the context of waning immunity at an individual or population level.
CONCLUSION
Marked viral diversity and adaptation of other RNA viruses such as HIV, HCV, and influenza to 
host selective pressures have been a barrier to successful treatment and vaccination to date. 
Although SARS-CoV-2 is less diverse and adaptable, the D614G variant and the K203/R204 and 
Delta variants have emerged by either nucleotide mutation or homologous recombination during 
the rapid, global spread of the virus and do appear to have functional impact. It will therefore be 
critical to continue molecular surveillance of the virus and elucidate the functional consequences 
of any newly emerging viral genetic changes to guide development of diagnostics, antivirals, and 
universal vaccines and to target conserved and potentially less mutable SARS-CoV-2 elements. 
The ability of SARS-CoV-2 to introduce new TRS motifs throughout its genome with the poten-
tial to introduce both novel sub-genomic RNA transcripts and coding changes in its proteins may 
add to these challenges. 
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